Lilly Gets Its Wish: STAR Results Show Evista Reduces Breast Cancer Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.